Neumora Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

NMRA$0.49-3.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Financial Statements (Unaudited)Condensed Consolidated Balance Sheets

Condensed Cons olidated Balance Sheets

(in thousands)

	September 30, 2025	December 31, 2024
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$129,071	$142,148
Restricted cash	—	1,213
Short-term marketable securities	42,454	165,430
Prepaid expenses and other current assets	5,557	5,264
Total current assets	177,082	314,055
Property and equipment, net	80	1,140
Operating lease right-of-use assets	474	1,777
Other assets	197	—
Total assets	$177,833	$316,972
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$549	$3,307
Accrued liabilities	24,982	24,593
Early exercise liability, current portion	55	133
Operating lease liabilities, current portion	256	1,853
Total current liabilities	25,842	29,886
Long term debt, net	19,563	—
Operating lease liabilities, noncurrent	267	—
Early exercise liability, net of current portion	—	22
Total liabilities	45,672	29,908
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock	16	16
Additional paid-in capital	1,256,835	1,234,207
Accumulated other comprehensive income	9	62
Accumulated deficit	(1,124,699)	(947,221)
Total stockholders’ equity	132,161	287,064
Total liabilities and stockholders’ equity	$177,833	$316,972

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.